‘Fidson is committed to providing affordable, high quality pharmaceuticals to Nigerians’

FIDSON Healthcare Plc has reiterated its commitment to providing high quality healthcare products to Nigerians, despite challenges posed by COVID-19 pandemic and the consequential effects on the economy.

The founder and Managing Director of Fidson Healthcare Plc. Dr. Fidelis Ayebae, stated that from inception in 1995, the firm has always endeavoured to offer customers the best in pharmaceuticals and healthcare services, in pursuit of its aim of becoming the leading pharmaceutical company in Africa.

He noted this at the company’s annual general metting (AGM), held at the its headquarters in Lagos. He explained that the organisation’s improved performance was due largely to the combined result of volume growth in key product lines and improved efficiency in its supply chain.

He said: “As an organisation, we are committed to intensifying focus on these performance drivers, going forward. This stellar performance has further strengthened our position as a leader in the healthcare industry.”

He said Fidson is poised to meet the demand for pharmaceutical products across Nigeria, with deliberate increase in production capacity to deliver dosage forms in key therapeutic areas.

“Today, the company boasts of over 250 NAFDAC registered brands, and is deliberately expanding production capacity at its current World Health Organisation Good Manufacturing Practice (WHO-CGMP) compliant facility in Sango-Ota, Nigeria,” he said.

Chairman Board of Directors, Fidson Healthcare Plc., Mr. Segun Adebanji, disclosed that the vision for expansion has driven the organisation to invest heavily in machinery and expertise of the highest quality.

“The expansion project has progressed well and led to the partnership agreement signed with GSK Nigeria for contract manufacturing. Fidson plans to sustain its vision of running one of the best pharmaceutical manufacturing facilities in Sub-Saharan Africa,” he said.

He explanianed that shareholders of Fidson Healthcare Plc would receive a dividend of 25 kobo per share. This was unanimously approved by the shareholders at the 22nd Annual General Meeting.

“This dividend is an improvement on the 15 kobo per share paid in the 2019 financial year,” he said.